arginyl-glycyl-aspartic acid has been researched along with Coronary Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Proimos, G | 1 |
| Polokoff, MH; Shebuski, RJ; Sitko, GR; Stabilito, IJ | 1 |
1 review(s) available for arginyl-glycyl-aspartic acid and Coronary Disease
| Article | Year |
|---|---|
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Receptors, Thrombin; Thrombin; Tirofiban; Tyrosine | 2001 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Coronary Disease
| Article | Year |
|---|---|
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Topics: Animals; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Drug Combinations; Electric Stimulation; Female; Fibrinolytic Agents; Hemodynamics; Heparin; Male; Myocardial Reperfusion; Partial Thromboplastin Time; Peptides; Platelet Aggregation; Recombinant Proteins; Recurrence; Snake Venoms; Tissue Plasminogen Activator | 1990 |